Indaptus Therapeutics, Inc. — Q1 2023 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2023. Indaptus is a clinical-stage biotechnology company developing immunotherapies; it has no approved products and has not generated product revenue. Its lead candidate, Decoy20, is being evaluated in a Phase 1 trial in patients with advanced solid tumors. The trial began in December 2022 and is an open-label, multicenter dose-escalation and expansion study.
Financial performance and position
| Metric | Q1 2023 / March 31, 2023 | Prior period / comparison |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $1.88 million | $1.30 million in Q1 2022 |
| General and administrative expense | $2.58 million | $2.10 million in Q1 2022 |
| Total operating expenses | $4.46 million | $3.40 million in Q1 2022 |
| Other income, net | $0.20 million | $0.04 million in Q1 2022 |
| Net loss | $4.25 million; $0.51 per share | $3.37 million; $0.41 per share in Q1 2022 |
| Operating cash flow | $(4.96) million | $(3.12) million in Q1 2022 |
| Cash, cash equivalents and marketable securities | $21.68 million | $26.43 million at December 31, 2022 |
| Total assets / total liabilities | $23.14 million / $1.96 million | $28.06 million / $3.43 million at December 31, 2022 |
No debt balance is reported. Liabilities include operating lease obligations of approximately $236,506, following lease remeasurement, and current accounts payable and other liabilities. The filing provides no operating margin; the company reported an operating loss of $4.46 million. Cash and marketable securities declined by approximately $4.75 million from year-end.
Changes versus Q1 2022
- Operating expenses rose 31%; R&D increased 45%, primarily due to higher payroll and Phase 1 trial costs. Management expects R&D expense to rise as the trial progresses.
- G&A increased 22%, mainly from legal, recruitment and other professional fees, partly offset by lower D&O insurance and payroll costs.
- Net loss increased 26%. Higher interest income and realized gains on marketable securities partly offset the increase in operating costs.
- Operating cash use increased by approximately $1.84 million, reflecting greater R&D and G&A spending. There was no financing cash flow in either quarter.
Outlook, risks and unusual items
- Management estimates existing cash, cash equivalents and marketable securities will fund ongoing activities into the second quarter of 2024. The company expects continuing losses and says additional financing will be needed; plans to raise capital or pursue collaborations are not within its full control and are not assessed as probable.
- Potential funding sources include equity or debt financing, collaborations and licensing. The company reported an ATM capacity of up to $6.3 million and a Lincoln Park purchase agreement of up to $20 million; it had made no sales under either arrangement as of the filing. Further equity issuance could dilute shareholders.
- Key risks include clinical-trial safety, enrollment, timing and outcome; reliance on third-party research and manufacturing providers; capital availability; and the possibility that Decoy20 never obtains regulatory approval or commercial acceptance. Macroeconomic volatility, inflation, higher interest rates and banking-market disruption may hinder financing and operations.
- The company settled the LTS arbitration on February 7, 2023, paying €800,000 (approximately $860,000); it reported no other pending material legal proceedings.
- The San Diego office lease was extended through October 31, 2025 by an amendment executed April 19, 2023. The filing reports a $236,506 incremental right-of-use asset and lease liability. Verify the timing and accounting presentation, given the amendment date after quarter-end and the amount recorded in the March 31 balance sheet.
- As of March 31, 2023, 8,401,047 common shares were outstanding; the filing also reports 3,090,787 warrants and 1,928,623 options outstanding, representing potential dilution. Management said disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether clinical-trial enrollment, safety findings and development milestones support the company’s stated cash runway.
- Current cash burn, marketable-security availability and the timing and terms of any future financing; confirm remaining ATM capacity and Lincoln Park purchase-agreement conditions.
- The lease amendment’s effective date, quarter-end recognition and resulting lease obligations.
- Potential dilution from outstanding options and warrants, and any subsequent share issuances.
- Whether any new legal, regulatory, manufacturing or clinical developments have arisen since the May 11, 2023 filing.